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Objectives: To present preliminary results of minimally invasive endovascular embolization 
as a treatment of symptomatic adenomyosis or adenomyosis with fibroids and to assess the 
long-term clinical outcome. 
Material and methods: Between 2015 and 2020 twelve patients with symptomatic 
adenomyosis or adenomyosis with fibroids underwent uterine artery embolization (UAE). All 
patients were evaluated in terms of patient’s overall satisfaction, relief of clinical symptoms, 
reintervention and hysterectomy as well as menopause rates.
Results: Mean age on admission was 48 years. Reported symptoms included: dysmenorrhea 
with the mean VAS score of 7.8, menorrhagia and problems with urination. Successful 
embolization was achieved in all patients (100%). A reduction in pelvic pain intensity 
assessed using VAS was observed in 11/12 (92%) of the patients — pain decreased by 6.2 
points on average (from 7.8 to 1.6 pts). In one patient (8%) the recurrence of pain was 
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observed. All patients reported decrease of menstrual bleeding and consequently improvement
of everyday life quality. Avoidance of hysterectomy was achieved in 83% of the women. Five 
patients experience absence of menstrual periods for at least 12 months after the embolization 
resulting in menopause rate of 42%. Ten patients (83%) reported to be very or fairly satisfied 
with the results and would recommend this treatment to a friend. 
Conclusions: Uterine artery embolization might be safe and effective method of treatment for
patients with symptomatic adenomyosis with or without fibroids with very high rate of 
satisfied patients.
Key words: uterine artery embolization; adenomyosis; long-term results; minimally invasive
INTRODUCTION
Adenomyosis describes a benign uterine disorder in which endometrial glandular 
tissue is located within the uterine myometrium [1]. The most common clinical presentations 
of adenomyosis include cyclical uterine pain, abnormal menstrual bleeding and infertility [2]. 
Additionally, adenomyosis often co-exists with other uterine disorders, most commonly 
leiomyoma, endometriosis and endometrial polyps which makes the diagnosis challenging 
and difficult [3]. Traditionally, adenomyosis was associated with multiparous middle-aged 
woman suffering from menorrhagia, however, with recent availability and accessibility of 
advanced imaging techniques especially magnetic resonance imaging (MRI) and transvaginal 
ultrasound (TVUS), it is now diagnosed in young patients with wide range of clinical 
symptoms or even asymptomatic patients [4, 5]. Nonetheless, adenomyosis remains under-
reported and under-diagnosed with estimated prevalence of 35–40% according to some 
authors [6]. Treatment modalities include surgical, pharmacological and minimally invasive 
methods. Hysterectomy which is the definitive cure is not an option for women willing to 
preserve their fertility. Conservative treatment focuses on either inhibition of enzymes 
producing the prostaglandins responsible for painful cramping during menstruation (non-
steroidal anti-inflammatory drugs) or endometrial proliferation inhibiting drugs (e.g., oral 
contraceptive pills, levonorgestrel, danazol and aromatase inhibitors) [7, 8]. Minimally 
invasive interventional radiological procedures are promising therapies for patients who 
desire future fertility. They include thermal ablation (MRI or ultrasound-guided) and uterine 
artery embolization (UAE) [9–11]. Long-term follow-up showed that patients with 
symptomatic adenomyosis who underwent UAE reported high rate of clinical improvement 
and avoided hysterectomy in over 80% of cases [12]. 
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Objectives
The aim of this study is to present our experience with UAE as a treatment of 
symptomatic adenomyosis or adenomyosis with fibroids and to assess the long-term clinical 
outcome. 
MATERIAL AND METHODS
This retrospective preliminary study was conducted in a clinical hospital in Poland. It 
evaluated 12 patients with symptomatic adenomyosis or adenomyosis with fibroids who 
presented between 2015 and 2020 and underwent UAE. All procedures were performed in 
accordance with the institutional ethical standards and with the 1964 Helsinki Declaration. 
Informed consent was obtained from all individual participants included in the study. 
All patients with adenomyosis with or without concomitant fibroids were assessed for 
treatment by an experienced gynecologist. After obtaining a medical history, baseline 
symptoms were categorized into following categories: menstrual bleeding characteristics, 
pelvic pain (assessed by VAS score from 0 to 10 — 0 representing lack of pain and 10 
unbearable pain), urinary discomfort and health-related quality of life items (limitations in 
daily activities, energy/mood, self-consciousness and sexual function). Afterwards, each 
patient underwent physical examination and TVUS followed by an MRI study. All data was 
then evaluated by an interventional radiologist for possible endovascular treatment. Additional
laboratory tests included platelet count, clotting time and renal functions markers (creatinine 
and glomerular filtration rate) were performed. The methods and procedures used in this study
comply with the ethical standards. The study was conducted according to the Helsinki 
Declaration. 
Endovascular embolization
All endovascular procedures were carried out in the angio suite with a digital 
subtraction angiography (DSA) system (Artis Zee, Siemens AG, Erlangen, Germany). In local
anesthesia femoral artery was punctured and bilateral selective catheterization of uterine 
arteries was performed using a coaxial system microcatheter. Embolization was performed 
with microspheres (500–900 µm) until complete stasis of contrast media in the distal 
ascending segment of the uterine artery on both sides. During the procedure, additional 
analgesic treatment (ketoprofen, paracetamol and morphine) was administered if needed. 
Following the procedure all patients received additional analgesic treatment and were 
monitored at the Department of Gynecology.
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Follow-up 
Clinical outcome was assessed based on a direct contact with a patient or structured 
telephone survey during the long-term follow-up period (range from 4 to 58 months). The 
evaluation included: patient’s overall satisfaction, relief of clinical symptoms, reintervention 
and hysterectomy as well as menopause rates. We also inquired whether the patient would 
recommend this treatment to a friend. 
RESULTS
A total of 12 patients met the inclusion criteria. Mean age on admission was 48 years 
(from 39 to 56). Four patients (33%) were diagnosed with pure adenomyosis and eight (67%) 
with adenomyosis with fibroids. Six patients (50%) had history of pregnancy and labor. 
Reported symptoms included: dysmenorrhea (92%) with the mean VAS score of 7.8 (range 
from 6 to 10), menorrhagia with menstrual clots (58%), menorrhagia without menstrual clots 
(33%) and problems with urination (8%). As far as health-related quality of life items were 
concerned, 50% of women complained about limitation of daily activities and low energy due 
to heavy menstrual bleeding and 33% had problems with their sexual life. Successful 
embolization was achieved in all patients (100%). There were no major procedure-related 
complications. On average patients spent two days in the hospital. 
A reduction in pelvic pain intensity assessed using VAS was observed in 11/12 (92%) 
of the patients - pain decreased by 6.2 points on average (from 7.8 to 1.6 pts) in the follow-up 
period (from 4 to 58 months, mean 39 months). In one patient (8%) the recurrence of pain was
observed two months after the embolization. This patient required hysterectomy. All patients 
reported decrease of menstrual bleeding and consequently improvement of everyday life 
quality. In one patient the decrease was not satisfactory, and she underwent secondary 
hysterectomy. Thus, avoidance of hysterectomy was achieved in 83% of the women. Five 
patients experience absence of menstrual periods for at least 12 months after the embolization 
resulting in menopause rate of 42%. Most patients (10/12, 83%) reported to be very or fairly 
satisfied with the results and would recommend this treatment to a friend. 
Demographic details and long-term results are presented in Table 1.
DISCUSSION
Adenomyosis remains a problematic diagnosis due to its variable presentation and 
common coexistence of other gynecologic disorders. Contrast-enhanced MRI and 
transvaginal ultrasound are currently the most accurate imaging techniques for the diagnosis 
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of adenomyosis [13]. Although hysterectomy is considered the only definite treatment both 
hormonal and minimally invasive embolization treatments are widely implemented. The 
former aims to reduce the junctional zone thickness whereas the latter results in the reduction 
of uterine volume [14, 15]. Both therapeutic approaches are reported to be successful, 
especially in view of the short-term results [16, 17]. However, according to Pelage et al., even
if short-term results of endovascular treatment of patients with adenomyosis are promising, 
the long-term clinical outcome is disappointing and nearly 50% of treated patients do not 
show clinical improvement [18]. Similarly, authors of a study which included 54 patients with
symptomatic adenomyosis treated with UAE observed a recurrence rate of 38% [19].
On the other hand, authors of a study who evaluated seven-year clinical results of 
UAE among patients with symptomatic adenomyosis using UFS-Qol questionnaire observed 
that 76% of the patients reported to be asymptomatic [12]. Similarly high rate of symptom 
improvement was achieved by Bae et al. [20], who followed up 50 patients with pure 
adenomyosis for four years after endovascular treatment. In our study, all patients reported 
decrease of menstrual pain although in one case the decrease was not satisfactory. Average 
VAS score after the treatment was 1.6 which corresponded to mild pain (decrease from 
average 6.2 points before the embolization which corresponded to moderate/severe pain) [21].
Overall effectiveness of UAE appears to be higher compared to conservative surgical methods
which include endomyometrial ablation/resection and laparoscopic myometrial 
electrocoagulation [22].
In terms of patients who undergo hysterectomy despite the endovascular treatment, the
results range from 10 to 28% according to above-mentioned studies [12,19,20]. Our results 
confirm these findings — avoidance of hysterectomy was achieved in 83% (2/12) of the 
patients. Thus, the mean failure rate is comparable with other minimally invasive surgical 
methods [23]. 
In our study, we observed the occurrence of menopause in 42% of patients within first 
year after embolization. Premature induction of menopause and subclinical diminution of 
ovarian functional reserve after UAE is a known complication of endovascular treatment [24].
However, one should keep in mind, that the mean age of followed-up patients was 48 (range 
from 39 to 56) with only one patient younger that 40 years, whereas the average age of 
women for reaching menopause is 51 years in countries like Poland [25]. 
We are aware that our study has limitations. First and foremost, the relatively small 
group of patients which limits the validity of data, and which makes strong conclusions 
hazardous. In addition to that, the small sample size precludes more detailed statistical 
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analysis. Finally, heterogeneity of analyzed patients. When adenomyosis occurs with uterine 
fibroids occur, it is very difficult to determine if the symptoms are caused by one disorder or 
another. Since pure adenomyosis is a relatively rare condition, we also included the patients 
with coexistent fibroids. 
CONCLUSIONS
In conclusion, despite the limited number of patients, our preliminary study showed 
promising results confirming that uterine artery embolization might be a safe and effective 
method of treatment for patients with symptomatic adenomyosis with or without fibroids with
very high rate of satisfied patients. 
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Table 1. Demographic details and long-term results. 
Patients — 12 (n, %) Adenomyosis — 4, 
33%
Adenomyosis with 
fibroids — 8, 67%
Demographic data
Mean age (years) (min – max) 48 (39 to 56)




Menorrhagia with menstrual clots (n, %)
Menorrhagia without menstrual clots (n, %)
Problems with urination (n, %)









Pain reduction (n, %)
Hysterectomy (n, %)
Decrease of menstrual bleeding (n, %)
Menopause (n, %)






Figure 1. A–C. 45-year-old patient with adenomyosis confirmed by MRI; D. Initial 
angiography confirmed the presence of enlarged uterine arteries. Bilateral selective 
angiography of uterine arteries before embolization
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Figure 2. Rating VAS scale of the reported pelvic pain — before and after embolization
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